#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Ning Li Email
VP, Molecular Biology & Platform Discovery . Selecta Biosciences
How to contact Ning Li
Join and see Ning's contact info for free!Current Roles
Employees:
60Revenue:
$9.3MAbout
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTORâ„¢ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. The company's first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.Selecta Biosciences Address
65 Grove StreetWatertown, MA
United States